Survival Analysis of Adult Patients with Acute Myeloid Leukemia (AML) Treated with Intensive Chemotherapy: Results of a Mexican National AML Registry

Demichelis, Roberta; Zapata, Nidia; Leyto, Faustino; Terreros, Eduardo; Carrillo, Ángel; Montaño, Efréen; Aviles-Solis, Juan Carlos; Colunga, Perla; Díaz, Guillermo Robles; Amador, Fabián; Martinez, R.; Turrubiates, Francisco J.; Cabrera, Álvaro; Zaragoza, Alva; Espinoza, Ramiro; Gutiérrez, Ruth; Apodaca, Elia; Moreira, Carolina Campos Lima; García, Carolina J. García; Garcia, L.; Limón, Alejandro; Gómez, David Gómez; Rozen, Etta; Espinosa, Karla Adriana; Crespo, Erick; Meillón, Luis

doi:10.1016/j.clml.2019.07.074

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study from Brazil showed that AML-patients treated with intensive chemotherapy had a 5-year OS of 22% with an early mortality of 22% [42•]. In México, we recently showed the results of a multicenter experience of 525 adult-AML patients where the outcomes of patients treated with intensive chemotherapy are also inferior in comparison with developed countries with a 3-year OS of 34.8% and an early-mortality of 17.8% [43]. The high rate of induction-related mortality is very frequent in DC; it uses to be around 25% or as high as 39% in India [44,45].…”

Section: Barriers To Access To Therapy In Developing Countriesmentioning

confidence: 99%

Access to Therapy for Acute Myeloid Leukemia in the Developing World: Barriers and Solutions

Meillón-Garcı́a

Demichelis‐Gómez

2020

Curr Oncol Rep

View full text Add to dashboard Cite

Purpose of Review Acute myeloid leukemia (AML) is a costly disease, and its impact is greater in developing countries (DC). We will review the current concept of what are DC, compare the differences in the epidemiology and economic burden of this disease between developed and DC, and finally, analyze the barriers and possible solutions that DC should implement to achieve better results. Recent Findings DC is a frequently misunderstood name. The way we use to measure human development is changing, and multidimension metrics better define what are DC. With this in mind, we show the differences in the AML epidemiology and the impact of economic burden in DC. We analyze the barriers to access therapy from a clinician point of view, to show that most DC shared similar challenges but with a diverse healthcare structure. Finally, we provide several possible solutions for a more integrated and timely treatment that allows better results not only in terms of survival but with a better quality of life. Summary The economic burden of AML treatment in DC is high, and the results are poor. It is crucial to face this challenge and propose new treatment approaches to achieve better results.

show abstract

Section: Barriers To Access To Therapy In Developing Countriesmentioning

confidence: 99%

Access to Therapy for Acute Myeloid Leukemia in the Developing World: Barriers and Solutions

Meillón-Garcı́a

Demichelis‐Gómez

2020

Curr Oncol Rep

View full text Add to dashboard Cite

show abstract

Current State of Diagnosis and Treatment of Acute Myeloid Leukemias in Adult Patients in the Republic of Kazakhstan

Клодзинский¹,

Pivovarova²,

Turgunova

et al. 2022

Клиническая онкогематология

View full text Add to dashboard Cite

Background. In recent years, the incidence of acute myeloid leukemias (AML) globally has continued to increase. Current approaches to AML treatment remain a challenge for the healthcare in many countries. There are only single studies on the analysis of AML state in adult patients in Kazakhstan. Over the last 10 years in Kazakhstan, no results of AML monitoring in adult patients have been available. Aim. To study the characteristics of clinical course and treatment outcomes in AML in the Central Kazakhstan and in the city of Ust-Kamenogorsk, East Kazakhstan Region. Materials & Methods. The study enrolled 86 AML patients (46 men and 40 women), the median age was 60.5 years (range 19-86 years); 64 (74.4 %) patients were from Karaganda Region, 15 (17.4 %) patients were from Ust-Kamenogorsk, and 7 (8.1 %) patients were from other regions of Kazakhstan. The analysis covered the structure and treatment outcomes in newly diagnosed AML patients within the period from 2018 to June, 2021. Statistical analysis of data was made using SPSS Statistics 23.0. Results. The analysis of diagnostic techniques showed that myelogram and immunophenotyping were used in 98.8 %, cytogenetic assay was made in 18 %, and molecular analysis was performed in 59.3 % of patients. The “7+3” remission induction was administered in 54.6 % of patients, 20.9 % of patients were treated with hypomethylating agents and low doses of cytarabine, and 24.4 % of patients were on palliative and supportive therapy. Out of 47 patients treated with the “7+3” remission induction, complete clinical hematological remission was reached in 29 (61.7 %) patients. Primary resistance was reported in 21.3 % of patients. Early mortality (death within 30 days from the start of induction) rate was 17 %. High-dose cytarabine consolidation (1.5-3 g/m<sup>2</sup> twice every other day, 2-3 courses) was administered to 75.8 % of patients. All the allogeneic bone marrow transplantations (n = 7) were performed at the National Research Center for Oncology and Transplantology in Nur-Sultan. The median overall survival in the group of standard “7+3” chemotherapy recipients was 11 months (range 1-83 months), and the median disease-free survival was 9 months (range 2-79 months). Conclusion. The study presents the characteristics and short-term outcomes of treatment of adult AML patients in Kazakhstan. The study limitations were a short follow-up period and enrollment of patients only from two regions of Kazakhstan. It is necessary to continue improving the current standards of AML diagnosis and treatment of adult patients.

show abstract

Survival Analysis of Adult Patients with Acute Myeloid Leukemia (AML) Treated with Intensive Chemotherapy: Results of a Mexican National AML Registry

Cited by 2 publications

References 0 publications

Access to Therapy for Acute Myeloid Leukemia in the Developing World: Barriers and Solutions

Access to Therapy for Acute Myeloid Leukemia in the Developing World: Barriers and Solutions

Current State of Diagnosis and Treatment of Acute Myeloid Leukemias in Adult Patients in the Republic of Kazakhstan

Contact Info

Product

Resources

About